Home › Multiple Myeloma
Multiple Myeloma clinical trials recruiting in the U.S.
239 studies for Multiple Myeloma are recruiting participants at sites across the United States.
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
Cities with the most studies
- New York City, NY59 studies
- Boston, MA45 studies
- Atlanta, GA42 studies
- Houston, TX39 studies
- Durham, NC36 studies
- Nashville, TN31 studies
- Denver, CO26 studies
- St. Louis, MO26 studies
- Rochester, MN25 studies
- Columbus, OH25 studies
- Chicago, IL24 studies
- Milwaukee, WI23 studies
- Baldwin Park, CA23 studies
- Seattle, WA22 studies
- Miami, FL22 studies
- Salt Lake City, UT22 studies
- Edison, NJ21 studies
- Washington, DC21 studies
- Charlotte, NC21 studies
- Queens, NY19 studies
- Detroit, MI19 studies
- Jacksonville, FL19 studies
- Dallas, TX18 studies
- San Francisco, CA17 studies
- Omaha, NE17 studies
- Birmingham, AL17 studies
- Cincinnati, OH17 studies
- Winston-Salem, NC16 studies
- Cedar Rapids, IA16 studies
- Phoenix, AZ16 studies
- Philadelphia, PA16 studies
- Tampa, FL15 studies
- Los Angeles, CA15 studies
- Clifton, NJ15 studies
- Portland, OR14 studies
- New Rochelle, NY14 studies
- Cleveland, OH14 studies
- Irvine, CA14 studies
- Staten Island, NY13 studies
- Greenburgh, NY13 studies
By state
- Alabama22 studies
- Arizona28 studies
- Arkansas9 studies
- California68 studies
- Colorado36 studies
- Connecticut17 studies
- Delaware3 studies
- District of Columbia10 studies
- Florida54 studies
- Georgia49 studies
- Idaho3 studies
- Illinois33 studies
- Indiana18 studies
- Iowa19 studies
- Kansas12 studies
- Kentucky15 studies
- Louisiana10 studies
- Maine4 studies
- Maryland23 studies
- Massachusetts47 studies
- Michigan27 studies
- Minnesota31 studies
- Missouri27 studies
- Montana5 studies
- Nebraska19 studies
- Nevada3 studies
- New Hampshire4 studies
- New Jersey37 studies
- New Mexico5 studies
- New York74 studies
- North Carolina53 studies
- North Dakota5 studies
- Ohio46 studies
- Oregon21 studies
- Pennsylvania23 studies
- Rhode Island6 studies
- South Carolina8 studies
- South Dakota3 studies
- Tennessee31 studies
- Texas53 studies
- Utah22 studies
- Virginia20 studies
- Washington30 studies
- West Virginia3 studies
- Wisconsin30 studies
Recently updated studies
18F-Fluciclovine PET/CT in Multiple Myeloma
RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated Nov 12, 2026 · NCT06103838MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06152575Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Nov 12, 2026 · NCT02682667Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
RecruitingPhase 3
Ages 18 to 79 · All sexes · Updated Nov 12, 2026 · NCT07285239Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07555938A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT05650632Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Recruiting
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT05312255Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT06993675At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT05969860A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT05137054cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Nov 4, 2026 · NCT05366881FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
RecruitingPhase 1
Ages 18 to 80 · All sexes · Updated Nov 4, 2026 · NCT07221032BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07009899Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06948084A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07393282A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07589634A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05201781A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Nov 3, 2026 · NCT07149857A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05552222A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05652335A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07258511A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT04634552Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
RecruitingObservational study
Ages 10 and older · All sexes · Updated Nov 3, 2026 · NCT06323447A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07099391Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07341867From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.